Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Prajna, Guha"'
Autor:
Diwakar Davar, Yujia Liu, Jason Laporte, Prajna Guha, Steven C Katz, Chandra C Ghosh, Lauren Cournoyer, Alizee Ballarin, Ilan B Layman, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Toll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of che
Externí odkaz:
https://doaj.org/article/a44effbe99ed410eaeba499fe1a1625d
Autor:
David Geller, Ashley Moody, Richard Carvajal, Cara Haymaker, Sunil Reddy, Jose Lutzky, Shailender Bhatia, Diwakar Davar, Bartosz Chmielowski, Theresa Medina, Eric Wehrenberg-Klee, Marlana Orloff, Rahul Sheth, Sapna P Patel, Robert Knight, Jason Laporte, Prajna Guha, Bryan Cox, Steven Katz, Paula Novelli, Joshua D Kuban, Ann-Marie Hulstine, Kamaneh Montazeri, Shaheer A Khan, Lindsay Thornton, Anthony Lucci, Vanessa Sarli, Salyna Meas, Chandra C Ghosh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/4699634df0af46c0a34fa5697092f712
Autor:
Nicholas A. DaSilva, Benjamin J. Barlock, Prajna Guha, Chandra C. Ghosh, Catherine E. Trebino, Jodi L. Camberg, Steven C. Katz, David C. Rowley
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract Myeloid-derived suppressor cells (MDSCs) promote immunosuppressive activities in the tumor microenvironment (TME), resulting in increased tumor burden and diminishing the anti-tumor response of immunotherapies. While primary and metastatic t
Externí odkaz:
https://doaj.org/article/bb926099cfb648d1a8e9534e9ec798c2
Autor:
Chandra Ghosh, Kyle O’Connell, Kara Heatherton, Jason Laporte, Prajna Guha, Bryan Cox, Steven Katz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5ce87588abea4aa0ae208656af22e94f
Publikováno v:
Biomedicines, Vol 10, Iss 3, p 655 (2022)
With the advent of cancer immunotherapy, there has been a major improvement in patient’s quality of life and survival. The growth of cancer immunotherapy has dramatically changed our understanding of the basics of cancer biology and has altered the
Externí odkaz:
https://doaj.org/article/6932c94d40064453b8e66d159588033a
Autor:
Mirela Stancu, Robert Knight, Jason Laporte, Prajna Guha, Steven C Katz, Jill E Slansky, Ashley E Moody, John C Hardaway, Ethan Prince, Kimberly R Jordan, Richard D Schulick, Abdul Saied, Vincent Armenio, Richard P Junghans
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
In recent years, cell therapy technologies have resulted in impressive results in hematologic malignancies. Treatment of solid tumors with chimeric antigen receptor T-cells (CAR-T) has been less successful. Solid tumors present challenges not encount
Externí odkaz:
https://doaj.org/article/5118535cc9e842ce850a0e39b1929165
Autor:
Louis F. Chai, John C. Hardaway, Kara R. Heatherton, Kyle P. O’Connell, Mikayla C. Lopes, Benjamin A. Rabinowitz, Chandra C. Ghosh, Prajna Guha, David Jaroch, Bryan F. Cox, Steven C. Katz
Publikováno v:
Vaccines, Vol 9, Iss 8, p 807 (2021)
Metastatic liver tumors have presented challenges with the use of checkpoint inhibitors (CPIs), with only limited success. We hypothesize that regional delivery (RD) of CPIs can improve activity in the liver and minimize systemic exposure, thereby re
Externí odkaz:
https://doaj.org/article/6fb5f456cae4492f8c6c1e505c93455d
Autor:
Chandra C. Ghosh, Kara R. Heatherton, Kyle P. O’ Connell, Ian S. Alexander, Deborah A. Greer, Jason LaPorte, Prajna Guha, Bryan F. Cox, Steven C. Katz
Publikováno v:
Cancer Gene Therapy. 29:1854-1865
Myeloid-derived suppressor cells (MDSCs) expand in response to malignancy and suppress responsiveness to immunotherapy, including checkpoint inhibitors (CPIs). Within the liver, MDSCs have unique immunosuppressive features. While TLR9 agonists have s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43ccd38fbf84598e7fc2d4be9075680
https://doi.org/10.1038/s41417-022-00484-z
https://doi.org/10.1038/s41417-022-00484-z
Autor:
Louis F. Chai, John C. Hardaway, Kara R. Heatherton, Kyle P. O'Connell, Jason P. LaPorte, Prajna Guha, Mikayla C. Lopes, Benjamin A. Rabinowitz, David Jaroch, Bryan F. Cox, Robert Knight, Steven C. Katz
Publikováno v:
Journal of Surgical Research. 272:37-50
Effective treatment of solid tumors requires multi-modality approaches. In many patients with stage IV liver disease, current treatments are not curative. Chimeric antigen receptor T cells (CAR-T) are an intriguing option following success in hematol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf869c95ee41bbec7c6820448937aad
https://doi.org/10.1016/j.jss.2021.11.001
https://doi.org/10.1016/j.jss.2021.11.001
Autor:
Catherine Trebino, Steven C. Katz, Jodi L. Camberg, David C. Rowley, Nicholas A. DaSilva, Benjamin J. Barlock, Chandra C. Ghosh, Prajna Guha
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-10 (2021)
Cell Death Discovery
Cell Death Discovery
Myeloid-derived suppressor cells (MDSCs) promote immunosuppressive activities in the tumor microenvironment (TME), resulting in increased tumor burden and diminishing the anti-tumor response of immunotherapies. While primary and metastatic tumors are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58c020de105d9a8c57a625b314871f85
https://doaj.org/article/bb926099cfb648d1a8e9534e9ec798c2
https://doaj.org/article/bb926099cfb648d1a8e9534e9ec798c2